Envisioning the future of early anticancer drug development

Timothy A. Yap; Shahneen K. Sandhu; Paul Workman; Johann S. De Bono

doi:10.1038/nrc2870

Envisioning the future of early anticancer drug development

Timothy A. Yap, Shahneen K. Sandhu, Paul Workman, Johann S. De Bono

Research output: Contribution to journal › Review article › peer-review

243 Scopus citations

Abstract

The development of novel molecularly targeted cancer therapeutics remains slow and expensive with many late-stage failures. There is an urgent need to accelerate this process by improving early clinical anticancer drug evaluation through modern and rational trial designs that incorporate predictive, pharmacokinetic, pharmacodynamic, pharmacogenomic and intermediate end-point biomarkers. In this article, we discuss current approaches and propose strategies that will potentially maximize benefit to patients and expedite the regulatory approvals of new anticancer drugs.

Original language	English (US)
Pages (from-to)	514-523
Number of pages	10
Journal	Nature Reviews Cancer
Volume	10
Issue number	7
DOIs	https://doi.org/10.1038/nrc2870
State	Published - Jul 1 2010
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/nrc2870

Cite this

@article{c21e0c830d174208890f95cd25b11633,

title = "Envisioning the future of early anticancer drug development",

abstract = "The development of novel molecularly targeted cancer therapeutics remains slow and expensive with many late-stage failures. There is an urgent need to accelerate this process by improving early clinical anticancer drug evaluation through modern and rational trial designs that incorporate predictive, pharmacokinetic, pharmacodynamic, pharmacogenomic and intermediate end-point biomarkers. In this article, we discuss current approaches and propose strategies that will potentially maximize benefit to patients and expedite the regulatory approvals of new anticancer drugs.",

author = "Yap, {Timothy A.} and Sandhu, {Shahneen K.} and Paul Workman and {De Bono}, {Johann S.}",

note = "Funding Information: The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is supported in part by a programme grant from Cancer Research UK. Support was also provided by the Experimental Cancer Medicine Centre (to The Institute of Cancer Research) and the National Institute for Health Research Biomedical Research Centre (jointly to the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research). T.A.Y. is a Cancer Research UK Clinical Research Fellow and P.W. is a Cancer Research UK Life Fellow.",

year = "2010",

month = jul,

day = "1",

doi = "10.1038/nrc2870",

language = "English (US)",

volume = "10",

pages = "514--523",

journal = "Nature Reviews Cancer",

issn = "1474-175X",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Envisioning the future of early anticancer drug development

AU - Yap, Timothy A.

AU - Sandhu, Shahneen K.

AU - Workman, Paul

AU - De Bono, Johann S.

N1 - Funding Information: The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is supported in part by a programme grant from Cancer Research UK. Support was also provided by the Experimental Cancer Medicine Centre (to The Institute of Cancer Research) and the National Institute for Health Research Biomedical Research Centre (jointly to the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research). T.A.Y. is a Cancer Research UK Clinical Research Fellow and P.W. is a Cancer Research UK Life Fellow.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - The development of novel molecularly targeted cancer therapeutics remains slow and expensive with many late-stage failures. There is an urgent need to accelerate this process by improving early clinical anticancer drug evaluation through modern and rational trial designs that incorporate predictive, pharmacokinetic, pharmacodynamic, pharmacogenomic and intermediate end-point biomarkers. In this article, we discuss current approaches and propose strategies that will potentially maximize benefit to patients and expedite the regulatory approvals of new anticancer drugs.

AB - The development of novel molecularly targeted cancer therapeutics remains slow and expensive with many late-stage failures. There is an urgent need to accelerate this process by improving early clinical anticancer drug evaluation through modern and rational trial designs that incorporate predictive, pharmacokinetic, pharmacodynamic, pharmacogenomic and intermediate end-point biomarkers. In this article, we discuss current approaches and propose strategies that will potentially maximize benefit to patients and expedite the regulatory approvals of new anticancer drugs.

UR - http://www.scopus.com/inward/record.url?scp=77954028523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954028523&partnerID=8YFLogxK

U2 - 10.1038/nrc2870

DO - 10.1038/nrc2870

M3 - Review article

C2 - 20535131

AN - SCOPUS:77954028523

SN - 1474-175X

VL - 10

SP - 514

EP - 523

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

IS - 7

ER -

Envisioning the future of early anticancer drug development

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this